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The strategy of price liberalisation and privatisation had been implemented in Sudan over the last 
decade, and has had a positive result on government deficit. The investment law approved recently has 
good statements and rules on the above strategy in particular to pharmacy regulations. Under the 
pressure of the new privatisation policy, the government introduced radical changes in the pharmacy 
regulations. To improve the effectiveness of the public pharmacy, resources should be switched 
towards areas of need, reducing inequalities and promoting better health conditions. Medicines are 
financed either through cost sharing or full private. The role of the private services is significant. A 
review of reform of financing medicines in Sudan is given in this study. Also, it highlights the current 
drug supply system in the public sector, which is currently responsibility of the Central Medical 
Supplies Public Corporation (CMS). In Sudan, the researchers did not identify any rigorous evaluations 
or quantitative studies about the impact of drug regulations on the quality of medicines and how to 
protect public health against counterfeit or low quality medicines, although it is practically possible. 
However, the regulations must be continually evaluated to ensure the public health is protected against 
by marketing high quality medicines rather than commercial interests, and the drug companies are held 
accountable for their conduct. 
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The World Health Organisation [1] has defined drug regulation as a process, which encompasses 
various activities, aimed at promoting and protecting public health by ensuring the safety, efficiency and 
quality of drugs, and appropriateness accuracy of information [1]. Medicines regulation is a key instrument 
employed by many governments to modify the behaviour of drug systems. The regulation of 
pharmaceuticals relates to control of manufacturing standards, the quality, the efficacy and safety of drugs, 
labelling and information requirements, distribution procedures and consumer prices [2]. To assure quality 
of medicines, in most countries registration is required prior to the introduction of a drug preparation into 
 the market. The manufacturing, registration and sale of drugs have been the subject of restricts regulations 
and administrative procedures worldwide for decades [3]. Nobody would seriously argue drugs should be 
proven to be 100% safe. No set of regulations could achieve that goal argue, because it is impossible and 
all drugs carry some risk [4].  
Stringent drug regulation was introduced across many countries in the 1960s following the 
thalidomide disaster, and had since been embraced by the industry as a commercial essential seal of safety 
and quality [5]. In spite of the measures, many countries, especially developing one face a broader range of 
problems. In several developing countries drug quality is a source of concern. There is a general feeling of 
high incidence of drug preparations that are not of acceptable quality [6]. For example, about 70% of 
counterfeit medicines were reported by developing countries [7]. Reports from Asia, Africa, and South 
America indicate 10% to 50% of consider using prescribed drugs in certain countries may be counterfeit 
[8]. For instance, in Nigeria fake medicines may be more than 60 -70% of the drugs in circulation [9], and 
109 children died in 1990 after being administered fake Paracetamol [10]. In Gambia the drug registration 
and control system resulted in the elimination of „drug peddlers‟ and certain „obsolete and harmful‟ drugs, 
as well as a large decrease in the percentage of brand and combination drugs [11]). The percentage of 
drugs failing quality control testing was found to be zero in Colombia, but 92% in the private sector of 
Chad [12]. Hence, it is very difficulty to obtain accurate data. The proportion of counterfeit drugs in the 
USA marketplace is believed to be small - less than 1 percent [12]. In [13] reported two cases of 
counterfeit medicines that found their way into legitimate medicine supply chain in the UK in 2004. 
Poor quality drug preparations may lead to adverse clinical results both in terms of low efficacy and in 
the development of drug resistance [14]. Regulations are the basic devices employed by most governments 
to protect the public health against substandard, counterfeit, low quality medicines, and to control prices. 
Thorough knowledge of whether these regulations produce the intended effects or generate unexpected 
adverse consequences is critical. The World Health Organisation (WHO) undertook a number of initiatives 
to improve medicines quality in its member states and promote global mechanisms for regulating the 
quality of pharmaceutical products in the international markets. Yet, there are not any WHO guidelines on 
how to evaluate the impact of these regulations. There are numerous reports concerning drug regulations 
[15], but the published work on the impact of these regulations on the quality of medicines moving in the 
international commerce has been scarce. Findings from most published studies lack comparable 
quantitative information that would allow for objective judging whether and by how much progress on the 
various outcomes have been made by the implementation of the pharmaceutical regulations. To ignore 
evaluations and to implement drug regulation based on logic and theory is to expose society to untried 
measures in the same way patients were exposed to untested medicines [15]. 
The present policy of the national health–care system in Sudan is based on ensuring the welfare of the 
Sudanese inhabitants through increasing national production and upgrading the productivity of individuals. 
A health development strategy has been formulated in a way that realises the relevancy of health objectives 
to the main goals of the national development plans. The strategy of Sudan at the national level aims at 
developing the Primary Health Care (PHC) services in the rural areas as well as urban areas. In Sudan 
2567 physicians provide the public health services (554 specialists, 107 medical registrars, 1544 medical 
officers, 156 dentists, and 206 pharmacists). Methods of preventing and controlling health problems are the 
following: 
 
 Promotion of food supply and proper nutrition;  
 An adequate supply of safe water and basic sanitation; 
 Maternal and child health-care; 
 Immunisation against major infectious diseases; 
 Preventing and control of locally endemic diseases; and 
 Provision of essential drugs. 
 
This will be achieved through a health system consisting of three levels (state, provincial and localities), 
including the referral system, secondary and tertiary levels. Pharmacy management should be coordinated and 
integrated with other various aspects of health. The following are recommended: 
 
 The community must be the focus of benefits accruing from restructures, the legislature should 
protect community interest on the basis of equity and distribution, handover the assets to the 
community should be examined; and communities shall encourage the transfer the management of 
health schemes to a professional entity.  
  The private sector should be used to mobilise and strengthen the technical and financial resources 
from within and outside the country to implement the services, with particular emphasis on 
utilisation of local resources. 
 The government should provide the necessary financial resources to guide the process of 
community management of pharmacy supplies. The government should be a facilitator through 
setting up standards, specifications and rules to help harmonise the private sector and establish a 
legal independent body by an act of parliament to monitor and control the providers. Government 
should assist the poor communities who cannot afford service cost, and alleviate social-economic 
negative aspects of privatisation. 
 The sector actors should create awareness to the community of the roles of the private sector and 
government in the provision of health and pharmacy services. 
 Support agencies should assist with financial and technical support, training facilities, 
coordination, development and dissemination of health projects, as well as evaluation of projects. 
 
AIMS AND OBJECTIVES 
 
The main purpose of this study is to analyse and determine the opinion of a group of pharmacists who 
are the owners or shareholders in the Sudanese medicine importing companies and their perception 
concerning the effects of the government‟s new Pharmacy, Poisons, Cosmetics and Medical Devices Act 
has had on the quality of medicines in Sudan. To achieve this purpose the following questions would be 
answered:  
 
(1)  Do the Sudan pharmacy legislations prohibit marketing of low quality medicines? 
(2)  What is the impact of the transfer of veterinary medicines registration system to the Ministry of 
Animal  Resources after the approval of the Pharmacy and Poisons Act 2001? 
(3)  Does pre-marketing analysis of medicines help to detect the counterfeit medicines? 
(4)  Does importation of non-registered
1
 medicines by the government and non- governmental 
organisations exacerbate the problem of low quality medicine if any? 
 
In Sudan, the researchers did not identify any rigorous evaluations or quantitative studies about the 
impact of drug regulations on the quality of medicines and how to protect public health against counterfeit 
or low quality medicines, although it is practically possible. However, the regulations must be continually 
evaluated to ensure the public health is protected against fake medicines by ensuring the exclusive 
marketing of high quality medicines rather than commercial interests, and the drug companies are held 
accountable for their conducts [16]. 
 
MEDICINES LEGISLATION FRAMEWORK IN SUDAN 
 
The availability of medicines in Sudan is controlled on the basis of safety, quality and efficacy. Thus, 
the government effects control in accordance with the Pharmacy, Poisons, Cosmetics and Medical Devices 
Act 2001 and its instruments. The Federal or State Departments of Pharmacy (DOP) and directives issued 
orders. The primary objective of both Federal and States‟ Departments of Pharmacy is to safeguard public 
health by ensuring all medicines and pharmaceuticals on the Sudan market meet appropriate standards of 
safety, quality and efficacy. The safeguarding of public health is achieved largely through the system of 
medicines‟ registration and licensing of pharmacy premises. 
The first Pharmacy and Poisons Act was enacted in 1939. This Act had been amended three times since 
then. In 2001 amendments, cosmetics and medical devices were also brought under its purview. Thus, the name 
was changed to Pharmacy, Poisons, Cosmetics and Medical Devices Act (hereafter the Act). The Act regulates 
the compounding, sale, distribution, supply, dispensing of medicines and provides different levels of control for 
different categories, e.g., medicines, poisons, cosmetics, chemicals for medical use and medical devices.  
The Act makes provision for the publication of regulations and guidelines by the Federal Pharmacy 
and Poisons Board (FPPB), the pharmaceutical regulatory authority and its executive arm - the Federal 
General Directorate of Pharmacy (FGDOP). The FGDOP regulates mainly four aspects of medicines use: 
safety, quality, efficacy and price. Traditionally, governments in many countries, particularly developed 
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All medicines should be registered by the General Directorate of Pharmacy to get marketing approval. Each manufacturer or 
importer must present extensive information on the product (or products) submitted to allow Technical Standing Committee for 
drug registration evaluates the quality, safety, efficacy and price of medicines.  
 nations have attempted to ensure the efficiency, safety, rational prescribing, and dispensing of drugs 
through pre-marketing registration, licensing and other regulatory requirements [17]. When applying to 
register the medicine manufacturers and importers are required to furnish the FGDOP with a dossier of 
information including among others, the indication of the medicine, its efficacy, side effects, 
contraindication, warnings on usage by high risk groups, price, storage and disposal [17].  
The role of the FGDOP includes among others: 
 
(1) Regulation and control of the importation, exportation, manufacture, advertisement, distribution, 
sale and the use of medicines, cosmetics, medical devices and chemicals; 
(2) Approval and registration of new medicines - the Act requires FGDOP should register every 
medicine before be sold or marketed. Companies are required to submit applications for the 
registration of medicines for the evaluation and approval; 
(3) Undertake appropriate investigations into the production premises and raw materials for drugs and 
establish relevant quality assurance systems including certification of the production sites and 
regulated products; 
(4) Undertake inspection of drugs‟ whole and retail sellers owned by both public or private sectors; 
(5) Compile standard specifications and regulations and guidelines for the production, importation, 
exportation, sale and distribution of drugs, cosmetics, etc. 
(6) Control of quality of medicines: This will be done by regular inspection and post-marketing 
surveillance;  
(7) Licensing of pharmacy premises (i.e., pharmaceutical plants, wholesalers and retail pharmacies); 
(8) Maintain national drug analysis laboratories for the pre- and post- marketing analysis of 
medicines; 
(9) Coordination with states departments of pharmacy to ensure the enforcement of the Act and its 
rules and directives. 
Health and Pharmacy Systems 
The health system in Sudan is characterised by heavy reliance on charging users at the point of access 
(private expenditure on health is 79.1 percent), with less use of prepayment system such as health 
insurance. The way the health system is funded, organised, managed and regulated affects health workers' 
supply, retention, and the performance. Primary Health Care was adopted as a main strategy for health-
care provision in Sudan and new strategies were introduced during the last decade, including: 
 
 Health area system. 
 Polio eradication in 1988. 
 Integrated management of children illness (IMCI) initiative. 
 Rollback malaria strategy. 
 Basic developmental need approach in 1997. 
 Safe motherhood, making pregnancy safer initiative, eradication of harmful traditional practices 
and emergency obstetrics‟ care programmes. 
 
The strategy of price liberalisation and privatisation had been implemented in Sudan over the last 
decades, and has had a positive result on the government deficit. The investment law [18] approved 
recently has good statements and rules on the above strategy in particular to health and pharmacy areas. 
The privatisation and price liberalisation in healthy fields has to re-structure (but not fully). Availability 
and adequate pharmacy supplies to the major sectors. The result is that the present situation of pharmacy 
services is far better than ten years ago. 
The government of Sudan has a great experience in privatisation of the public institutions, i.e., the 
Sudanese free zones and markets, Sudan telecommunications (Sudatel) and Sudan airlines. These 
experiences provide good lessons about the efficiency and effectiveness of the privatisation policy. 
Through privatisation, the government is not evading its responsibility of providing health-care to the 
inhabitants, but merely shifting its role from being a provider to a regulator and standard setter. Drug 
financing was privatised early in 1992. Currently, the Federal Ministry of Health (FMOH) has privatised 
certain non-medical services in hospitals such as catering services, security and cleanings. 
The overall goal of the CMS ownership privatisation is to improve access to essential medicines and 
other medical supplies in order to improve health status of the inhabitants particularly in far states (e.g., 
Western and Southern States). 
 Establishment of alternative ownership for the CMS can be achieved by selling the majority of shares 
to the private sector. This will achieve the following objectives: 
 
 High access to essential medicines of good quality and affordable prices to the states‟ population 
and governments. 
 Efficiency and effectiveness in drug distribution system to avoid the serious pitfalls and 
incidences that was reported during the last ten years in the CMS. 
 Equity by reaching all remote areas currently deprived from the formal drug distribution channels. 
 Improvement of the quality and quantity of delivery of medicines to the public health facilities. 
 
The above objectives are expected to: 
 
 Increase geographical and economic access to essential medicines in all states (i.e., in both rural 
and urban areas) to reach at least 80% of the population (currently less than 50% of population 
have access to essential medicines).  
 The tax collection from the new business becomes more efficient and will increase after 
privatisation. The tax revenues could be used to finance other health-care activities.  
 If the government reserves some shares (not more than 50%) in the new business, then its shares‟ 
profit could be used to finance free medicines project in hospitals outpatients‟ clinic, and other 
exempted medicines, e.g., renal dialysis and haemophilic patients‟ treatment.  
 
 
Privatisation of Public Pharmaceutical Supplies 
 
The term privatisation has generally been defined as any process that aims to shift functions and 
responsibilities (totally or partially) from the government to the private. More broadly meaning, it refers to 
the restriction of government's role and putting forward some methods or policies in order to strengthen the 
free market economy [19]. Privatisation can be an ideology (for those who oppose government and seek to 
reduce its size, role, and costs, or for those who wish to encourage diversity, decentralisation, and choice) 
or a tool of government (for those who see the private sector as more efficient, flexible, and innovative 
than the public sector) [19]. In [19] contends that “the invisible hand of the market is more efficient and 
responsive to the consumer needs and the public administrative budgets consume large portion of tax 
monies that could otherwise be used for service delivery”. The emphasis is on improving the efficiency of 
all public enterprises, whether retained or divested.  
Privatisation may take many forms including: 
 
 Elimination of a public function and its assignment to the private sector for financial support as 
well as delivery (police, and fire departments, schools, etc.). Opponents characterise this as “load-
shedding”. 
 Deregulation: the elimination of government responsibility for setting standards and rules 
concerning goods or services. 
 Assets sales: the selling of a public asset (city buildings, and sports stadiums) to private firms. 
 Vouchers: are the government provided or financed cards or slips of paper that permit private 
individuals to purchase goods or services from a private provider (food stamps) or circumscribed 
list of providers. 
 Franchising: the establishment of models by the public sector that is funded by government 
agencies, but implemented by approved private providers.  
 Contracting: the government financing of services, choice of service provider, and specification of 
various aspects of the services laid out in contracts with the private-sector organisation that 
produces or delivers the services. 
 User fees: public facilities such as hospitals that maximise their income or finance some goods 
from private sources, either through drug sales or other services. This kind of privatisation has 
been applied in Sudan since the early 1990s, as the health financing mechanism (especially for 
medicines). 
 
 In Sudan, the government has decided to distance itself from direct involvement in business, and thus 
divest most of its interests whether in loss or profit making public enterprises. The public reform 
programme was set firmly in the context of the broader reforms [19], which were introduced in 1992. It 
had become clear the previous policies had delivered led to poor results. This reform based on the transfer 
of activities vested with the government institutions to the private sector. It signalled the government 
intention to reduce its presence in the economy, to reduce the level and scope of public spending and to 
allow market forces to govern economic activities. Privatisation also forms part of the government strategy 
of strengthening the role of the private in the development to achieve the vision of the 25 years strategy in 
which the private sector will be the engine for economic growth. The privatisation started in 1992 by 
liberalisation of local currency, foreign exchange transactions, internal and external trade, prices and health 
services (e.g., user fee as a mechanism of drug financing and other services). This reform had led to greater 
reliance on individual initiative and corporate accountability rather than on government as a decision-
maker in business matters. 
The privatisation policy goal is to improve the performance of the public sector companies, so that 
they can contribute to the growth and the development of the economy by broadening ownership, 
participation in management, and stimulating domestic and foreign private investment. 
The following are the primary objectives, which have been defined in the government‟s policy 
statement on public sector reform [19]: 
 
 Improve the operational efficiency of enterprises that are currently in the public sector by 
exposing business and services to the greatest competition for the benefit of the consumer and the 
national economy. 
 Reduce the burden of public enterprises on the government‟s budget by spreading the shares‟ 
ownership as widely as possible among the population. 
 Expand the role of the private sector in the economy (permitting the government to concentrate on 
the public resources) on its role as provider of basic public services, including health, education, 
social infrastructure, and to compact the side effects of the privatisation.  
 Encourage wider participation of the people in the ownership and management of business. 
 
In pursuing the primary objectives the privatisation policy aims to transform the performance of most 
significant enterprises in the public sector and ensure liquidation of all viable and non-viable public 
enterprises as soon as possible through commercialisation, restructuring and divesture. 
Public sector reform efforts are thus aimed at reducing government dominance and promoting a larger 
role for the private sector, while improving government‟s use of resources. Movement towards those goals 
in some countries is supported by components of a structural adjustment loan, which helped initiate the 
programme and establish the legislative and institutional base. 
Opponents argue that the original objectives of state ownership were to ensure the corporate sector of 
the economy was in national hands rather than being controlled by either foreign investors or the 
minorities that enjoyed business dominance upon independence. A further objective was to use investment 
in state firms to accelerate development in a situation, in which private sector was reluctant to take risks. 
Medicines Legislation Framework in Sudan 
 
The availability of medicines in Sudan is controlled on the basis of safety, quality and efficacy. Thus, 
the government effects control in accordance with the Pharmacy, Poisons, Cosmetics and Medical Devices 
Act 2001 and its instruments. The Federal or State Departments of Pharmacy (DOP) and directives issue 
orders. The primary objective of both Federal and States‟ Departments of Pharmacy is to safeguard public 
health by ensuring all medicines and pharmaceuticals on the Sudan market meet appropriate standards of 
safety, quality and efficacy. The safeguarding of public health is achieved largely through the system of 
medicines‟ registration and licensing of pharmacy premises. 
The first Pharmacy and Poisons Act was enacted in 1939, and has been amended three times since. In the 
2001 amendments, cosmetics and medical devices were also brought under its purview. Thus, the name was 
changed to Pharmacy, Poisons, Cosmetics and Medical Devices Act (hereafter the Act). The Act regulates the 
compounding, sale, distribution, supply, dispensing of medicines and provides different levels of control for 
different categories, e.g., medicines, poisons, cosmetics, chemicals for medical use and medical devices.  
The Act makes provision for the publication of regulations and guidelines by the Federal Pharmacy 
and Poisons Board (FPPB), the pharmaceutical regulatory authority and its executive arm - the Federal 
 General Directorate of Pharmacy (FGDOP). The FGDOP regulates mainly four aspects of medicines use: 
safety, quality, efficacy and price. Traditionally, governments in many countries, particularly developed 
nations have attempted to ensure the efficiency, safety, rational prescribing, and dispensing of drugs 
through pre-marketing registration, licensing and other regulatory requirements. When applying to register 
the medicine manufacturers and importers are required to furnish the FGDOP with a dossier of information 
including: the indication of the medicine, its efficacy, side effects, contraindication, warnings on usage by 
high risk groups, price, storage and disposal.  
 
SUDAN MEDICINES’ QUALITY MEASURES 
 
The following summarises the quality measures of all medicines. 
 
 
REGISTRATION OF MEDICINES  
 
The FGDOP is responsible for the appraisal, and registration of all medicines and other 
pharmaceuticals for both human and veterinary use on the Sudan market. It is also responsible for the 
verification of the competence of manufacturing companies, the manufacturing plants, the ability to 
produce substances or products of high quality before registering these companies and allowing them to 
apply for registration of their products in Sudan. When necessary, visits conducted to those companies and 
their manufacturing units, to verify their compliance with good manufacturing practice recommended by 
the WHO. The applicant for registration of pharmaceutical product must submit all prescribed data and the 
certificates required under the WHO certification scheme for a pharmaceutical product moving into 
international commerce, and any other information that is necessary for assuring the quality, efficiency and 
stability of the product through its shelf life [19]. 
 
LICENSING OF PHARMACY PREMISES 
 
The licensing is a registration exercise to provide the DOP at state level (Federal level in case of local 
manufacturing plants) with the information necessary for the full implementation of the Act. Licenses are 
granted for a period of one year, and may be renewed at the end of December every year (applications to the 
relevant DOP before expiry of the current license). To improve the effectiveness of the public pharmacy, 
resources should be switched towards areas of need, reducing inequalities and promoting better health 
conditions. Medicines are financed either through cost sharing or full private. The role of the private services is 
significant. The present policy of the national health–care system in Sudan is based on ensuring the welfare of 
the Sudanese inhabitants through increasing national production and upgrading the productivity of individuals. 
The strategy of price liberalisation and privatisation had been implemented in Sudan over the last decade, and 
has had a positive result on government deficit. 
 
COMMERCIAL PRIVATE PHARMACIES 
 
These are private establishments retailing registered drugs and medical supplies at a mark-up of 18%. 
The source of the drugs and pharmaceuticals is private wholesalers. In 2002, though unlawful, the CMSPO 
started to sell its non-registered medicines to the private pharmacies. By the end of 2004, there were 779 
private pharmacies in Sudan. 
 
PEOPLE’S PHARMACIES  
 
These are quasi-public establishments retailing drugs and medical supplies below the market prices to 
improve access and availability of pharmaceuticals. They were founded in the early 1980s as a pilot study 
for a drug cost recovery system. Those differ from the private commercial pharmacies. Firstly, in having 
access to the CMSPO drugs, i.e., generic and large pack products, in addition the brand products from the 
private wholesalers. Secondly, the peoples‟ pharmacies are only owned by public organisations (e.g., 
hospitals, peoples‟ committees, trade unions and Non Governmental Organisations (NGOs)). Mark-up on 
cost for drugs from the CMSPO (35%), and from private drug wholesalers (profit margin is 10%). 
However, they have become commercialised now and operate in a similar way to private pharmacies. The 
total number of such pharmacies was approximately 200 in Sudan. 
  
Public Sector Medicines Supply System 
In Sub-Saharan Africa countries discussions about medicine distribution system reform have 
concentrated on ways to improve sustainability and quality of access to essential medicines. These 
discussions also include debate on the impact of privatisation of public drug supply organisations on 
effectiveness, efficiency, quality and cost of medicines in the public health facilities, as well as on the 
respective role of the public and private sectors. 
Until the mid 1980s, some governments in Africa (i.e., Mali and Guinea) assumed responsibility for 
providing drugs to their citizens. The private distribution of all drugs including aspirin was illegal. In many 
countries, including Sudan there were two parallel government distribution systems. The public health 
network of hospitals and health centres gratuitously distributed drugs. In the public sector pharmacies, the 
drugs were sold to the public at subsidised prices. 
During the 1990s, Sudan initiated a number of initiatives to establish drug-financing mechanisms as 
part of the health reform process and decentralised decision-making at a state level. In 1992 when a law 
was passed, medicines were no longer free of charge (i.e., privatised) in the public health system. The aim 
of the government is to increase equitable access to essential medicines, especially at the states‟ level. As a 
result the Central Medical Stores, which was responsible for medicines supply system of the public health 
facilities, became an autonomous drug supply agency, and was renamed as the Central Medical Supplies 
Public Corporation (CMS) and operated on cash-and-carry basis. It was capitalised and an executive board 
was installed. Since states and federal hospitals have to buy their own medicines, and other medical 
supplies. They organised their own transport means and distribution to their primary health-care facilities 
and hospitals. In addition, all hospitals became financially autonomous entities and have had to organise 
their own medicines procurement system. 
The public drug supply system has not been working well throughout Sub-Saharan Africa and this 
includes Sudan. There are serious shortages or no medicines at all, particularly in rural areas. A study in 
Cameroon found the rural health centres received only 65% of the stock designated for them, and 30% of 
the medicines that arrived at the centres did not reach the clients. The loss rate after arrival in hospitals was 
estimated at 40%. In Sudan, Graff and Evarard (2003) who visited the country on a WHO mission 
reported, “Although the cash-and-carry system took off well, but lack of sufficient foreign exchange 
hampered the CMS procurement activities and resulted in low stock levels of all medicines and even stock 
out of life-saving products. Hospitals had to purchase the medicines from elsewhere and often had to buy 
from private sector. Overall hospitals‟ budgets were tied to allocate drug budget and sales income was not 
sufficient to cover the purchase of needed medicines supplies. This resulted the medicines were not 
available most of the times. The in- or outpatients with their prescriptions were directed to the private 
pharmacies. In 2003, Khartoum Teaching Hospital-the biggest hospital in Sudan (not further than 5 km 
away from the CMS) had a medicine stock of only LS 83,000 (US$ 31). This would not fill one 
prescription for an anaemic patient as a result of renal failure. This is a common practice that patients or 
their relatives are given prescriptions to buy any pharmaceutical supplies that are needed including drugs 
and other disposables from private sector pharmacies. 
Many ministries of health, services‟ providers and researchers have identified many characteristics that 
lead to poor performance in Africa public drug supply systems. These characteristics include: 
 
(1)  Absence of competition: 
Competition is the best way to ensure the goods and services desired by the consumer are 
provided at the lowest economic cost. Given the customers (i.e., public health facilities) freedom 
of choice enables market forces to provide sustained pressures on companies to increase 
efficiency. Privatised companies generally operate in a competitive market environment. 
(2)  Insufficient funding: 
For example in Sudan with exception of Khartoum, Gezira and Gedaref states, all other states 
do not have enough funds to establish an efficient drug supply system. In spite of being profit-
making organisation, the CMS failed to avail such funds during the past 14 years. 
(3)  Inefficient use of available resources: 
Since CMS was established in early 1990s working as a profit-making organisation. Due to 
the absence of privatisation the CMS engaged in an instalment of repackaging joint venture 
pharmaceutical factory in 1999 and recently announced its commitment to build a pharmaceutical 
city with not less than US$ 20 million, despite the lack of life-saving medicines in the public 
 health facilities. Such amount could be sufficient to establish a reliable supply system for all states 
of Sudan. The lack of prioritisation is a typical symptom and sign of most public organisations. 
(4)  Poor management: 
There are a number of constraints inherent in operating government drug supply service. 
These constraints comprise: 
(a)  Civil servants are hired, rather than persons with business experience and skills. Managers 
confront different challenges in public setting. They are not easily hired or fired. The lack of 
accountability results from the lack of shareholders, who would be free to remove 
incompetent administrators. 
(b)  Even if the services can recruit outside of civil service, the wages are often too low to attract 
experienced managers. In addition, the managers do not share in dividends or other monetary 
activities as do private managers and incentives for doing well are often attenuated in a 
bureaucracy. 
(c)  There are cultural and structural conditions that promote corruptions including enormous 
pressure of wages earners to support an extended family and a strong incentive to more than 
their fixed government wage, traditional gift giving practice and a proprietary view of public 
offices. 
Advantages of Private Agencies 
There are many arguments in favour of privatisation of public institutions. Advocates of this method 
claim privatisation have the following advantages: 
 
 Privatisation is efficient and effective because it fosters and initiates competition. The competition 
among firms drives the cost down. Empirical studies clearly prove the cost of the services 
provided by the government is much higher than when the services are provided by private 
contractors. For example CMS‟s declared mark-up on cost (35%) amounted to 2.3 times the 
private mark-up (15%). In addition, private sector pays taxes, customs and other governmental 
fees (CMS exempted). 
 Privatisation also provides better management than the public management. Because decision 
making under privatisation is directly related to the costs and benefits. In other words, the 
privatisation fosters good management because the cost of the service is usually obscured. 
 Privatisation would help to limit the size of government at least in terms of the number of 
employees. On the other hand, it is a fact that overstaffing is common in publicly owned 
enterprises. 
 Privatisation can help to reduce dependence on a government monopoly, which causes 
inefficiencies and ineffectiveness in services. 
 Private sector is more flexible in terms of responding to the needs of citizens. Greater flexibility in 
the use of personnel and equipment would be achieved for short-term projects, part-time work, 
etc. Bureaucratic formalities are very common when government delivers the service. Less 
tolerance and strict hierarchy in bureaucracy are the reasons of the inflexibility in publicly 
provided services. 
Medicines Supply System 
The Act, for the first time in Sudan has given the responsibility of veterinary medicines to separate 
committees. The Ministry of Animal Resources took the law “in hand”, and started the registration of 
veterinary medicines and the licensing of the veterinary medicines premises. The conflict in the shared 
authorities between the Ministry of Health and the chairman of the FPPB lead to the freezing of the Board 
since October 2002. The FGDOP continues in the process of medicines registration, inspection of the 
pharmaceutical premises and the licensing as before establishment of the FPPB. 
The Act also obliges the states‟ governments to take all steps necessary to ensure compliance with 
marketing of registered medicines in licensed premises. But, the weaknesses of the regulatory 
infrastructure and lack of political commitment at state levels, the leakage of low quality, unregistered 
medicines to those states are highly suspected. This left the door widely opened for informal marketing of 
medicines particularly in far states. The states regulatory authorities should take the advantage of the legal 
authority granted by the Sudan constitution and the Pharmacy, Poisons, Cosmetics and the Medical 
 Devices Act 2001 to enforce the regulations and increase the frequency of the inspection visits to drug 
companies and retail pharmacies. 
Experience has shown the poor regulation of medicines can lead to the prevalence of substandard, 
counterfeit, harmful and ineffective medicines on the national markets and the international commerce. 
The Sudanese pharmaceutical legal framework was described as one of the strictest pharmaceutical system 
in the region. One of the great loopholes in this system was found to be the increased number of non-
registered medicines-governmental sources such as the Central Medical Supplies Public Organisation 
(CMSPO) and not-for-profit non-governmental Organisations (NGOs). Respondents were hopeful the 
double standard of rules enforcement would be lifted after the new national unity government take over, 
arguing the current situation in which public organisations (such as the CMSPO) sell non-registered 
medicines to the private pharmacies could enhance trading of counterfeit medicines and create unfair 
competition environment. 
 
RATIONAL FOR THE RESEARCH 
 
The drug distribution network in Sudan during the past few years was in a state of confusion. It 
consists of open market, drug vendors (known as home drug store), community (private) pharmacies, 
peoples' pharmacies, private and public hospitals, doctors‟ private clinics, NGOs clinics, private medicines 
importers (wholesalers), public wholesalers (i.e., Central Medical Supplies and Khartoum State Revolving 
Drug Fund) and local pharmaceutical manufacturers. It is a common phenomenon in far states (e.g., 
Western and Southern states) to see street sellers or mobile sellers (hawkers) sell cigarettes, perfumes, 
orange and astonishingly medicines that range from Paracetamol and Aspirin tablets to antibiotics and anti-
malarial drugs including injections. The medicines are usually left under the sun, and such conditions 
could facilitate the deterioration of the active ingredients.  
The states‟ departments of pharmacy statutorily licensed community and Peoples‟ pharmacies. A 
superintending pharmacist, who is permanently registered with the Sudan Medical Council and licensed, 
oversees the pharmacy any time it is opened for business [19]. With such pharmacies there should not be 
any serious of the sale of fake drugs. Unfortunately, however there are many pharmacies working without 
qualified pharmacists. 
This study is significant because the people right to health includes the right access to a reliable 
standard of health care and assurance the medicines received are not only genuine but also safe, effective, 
of good quality and affordable [20]. The Sudan government has designed various ways to protect the 
public against low quality medicines. It is expected to equip the departments of pharmacy especially in 
remote areas, poor states with material and trained staff to effectively perform duties.  
A recent unpublished post-marketing surveillance revealed that 35% of the CMSPO samples and 16% 
of the private companies (registered products) samples obtained from different pharmacy shops failed to 
pass the quality test [20]. However, very few studies if any have been undertaken to evaluate the impact of 
the regulations put in place by the government long time ago.  
This study should reveal strength and weaknesses of the legal pharmaceutical framework in Sudan 
from drug importers perspective. The findings of this investigation would be instructive to regulatory 
authorities in the developing countries. It also highlights how systematically the drug companies perceived 
the role of pharmacy regulations in assuring high quality of medicines and what suggestions (if any) they 
had to make in order to improve the regulatory framework. 
 
DISCUSSIONS 
In Sudan, with more than ten million people don‟t have adequate access to health care; twenty million 
inhabitants are without access to pharmacy, and a very low proportion of people being treated in hospitals. 
The investment, which is needed to fund the extension and improvement of these services, is substantial. 
Most governments in developing countries are ready to admit that they lack the financial resources for 
proper health and pharmacy schemes. Moreover, historically, bilateral and multilateral funding accounts 
for less than 10% of total investment needed. Thus the need for private financing is imperative. 
Many healthy utilities in developing countries need to work in earnest to improve the efficiency of 
operations. These improvements will not only lead to better services but also to enhanced net cash flows 
that can be re-invested to improve the quality of service. Staff productivity is another area where 
significant gains can be achieved. Failure of subsidies to reach intended objectives is due, in part, to lack of 
transparency in their allocation. Subsidies are often indiscriminately assigned to support investment 
programmes that benefit more middle and high-income families, which are already receiving acceptable 
 service. Consumption subsidies often benefit upper-income domestic consumers‟ substantially more than 
low-income ones. Many developing countries (Sudan is not an exception) are encouraging the participation 
of the private sector as a means to improve productivity in the provision of health and pharmacies services. 
Private-sector involvement is also needed to increase financial flows to expand the coverage and quality of 
services. Many successful private-sector interventions have been under taken. Private operators are not 
responsible for the financing of works, nonetheless they can bring significant productivity gains, which 
would allow the utility to allocate more resources to improve and extend services. Redressing productivity, 
subsidy and cross-subsidy issues before the private sector is invited to participate, has proven to be less 
contentious. 
Despite the constraints, over the last decade the rate of implementation of rural and peri-urban 
pharmacy supplies and healthy programmes has increased considerably, and many people are now being 
served more adequately. The following are Sudan experience in pharmacy supply and healthy projects: 
At community level: 
 
 Participatory approaches in planning, implementation and monitoring.  
 Establishment and training of reliable financial and maintenance management. 
 Sensitive timing of health and hygiene education.  
 
At state and national level: 
 
 Integrated multi-sectoral approach development. 
 Training approach and material development for state and extension staff. 
 Continuing support from integrated multi-sectoral extension team. 
 Establishment of technical support system. 
 Multi-sectoral advisory group including training and research institutions. 




Nanomedicine is defined as the medical application of nanotechnology. Nanomedicine can include a 
wide range of applications, including biosensors, tissue engineering, diagnostic devices, and many others. 
In the Center for Nanomedicine at Johns Hopkins, we focus on harnessing nanotechnology to more 
effectively diagnose, treat, and prevent various diseases. Our entire bodies are exposed to the medicines 
that we take which can lead to unpleasant side effects and minimize the amount of medicine that reaches 
the places where it is needed. Medications can be more efficiently delivered to the site of action using 
nanotechnology, resulting in improved outcomes with less medication. 
For example, treating cancer with current chemotherapy delivery techniques is like spraying an entire 
rose garden with poison in order to kill a single weed. It would be far more effective to spray a small 
amount of poison, directly on the weed, and save the roses. In this analogy, a cancer patient‟s hair follicles, 
immune cells, and epithelia are the roses being poisoned by the chemotherapy. Using nanotechnology, we 
can direct the chemotherapy to the tumour and minimize exposure to the rest of the body. In addition, our 
nanotechnologies are more capable of bypassing internal barriers, further improving upon conventional 
nanotechnologies. Not only is our approach more effective at eradicating tumours under Research), but it 
also results in much higher quality of life for the patient. 
Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical 
applications of nanomaterials and biological devices to nano-electric devices, to nano-
electronic biosensors, and even possible future applications of molecular nanotechnology such as 
biological machines. Current problems for nanomedicine involve understanding the issues related to 
toxicity and environmental impact of nano-scale materials and (materials whose structure is on the scale of 
nanometres, i.e. billionths of a metre). Functionalities can be added to nanomaterials by interfacing them 
with biological molecules or structures. The size of nanomaterials is similar to that of most biological 
molecules and structures; therefore, nanomaterials can be useful for both in vivo and in vitro biomedical 
research and applications. Thus far, the integration of nanomaterials with biology has led to the 
development of diagnostic devices, contrast agents, analytical tools, physical therapy applications, and 
drug delivery vehicles. Tracking movement can help determine how well drugs are being distributed or 
how substances are metabolized. It is difficult to track a small group of cells throughout the body, so 
scientists used to dye the cells. These dyes needed to be excited by light of a certain wavelength in order 
 for them to light up. While different colour dyes absorb different frequencies of light, there was a need for 
as many light sources as cells. A way around this problem is with luminescent tags. 
 
CONCLUSION AND RECOMMENDATION 
 
The study reveals the need for further research to find out how efficient the regulatory authorities at 
both federal and state levels are. The research also needed to discover whether or not counterfeit medicines 
are sold on the Sudanese market. 
From the data obtained in this article some general inferences could be made: 
 
1. The brad outlines remain intact, but preventing drug smuggling across national boarders (Sudan 
shares frontiers with 9 countries) is hard to police. 
2. The enforcement of the Act and its regulation governing the manufacture, importation, sale, 
distribution and exportation of medicines are not adequate enough to control the illegal 
importation and sale of medicines in Sudan. 
3. The splitting of the drug regulatory authority between two ministries and the marketing of 
unregistered medicines by public drug suppliers (namely the CMSPO, and RDFs), and NGOs 
undermine the quality of medicines and ultimately jeopardise the health of the people taking 
medication.  
 
In the light of the findings the following recommendations could be useful at various levels: 
 
1. There is an urgent need for government to implement the provisions of existing Act. 
2. The government should adequately equip and fund the National drug Analysis laboratories to start 
active post-marketing surveillance. 
3. A more spirited effort need to be made by the FGDOP and the States‟ Departments of Pharmacy 
to ensure all the medicines on the pharmacies‟ shelves are registered and come from legal sources. 
4. The states‟ departments of pharmacies are not in existence should be re-established and 
invigorated. They should be adequately funded to be able to acquire the necessary facilities for 
their operations. 
5. The CMSPO should stop importation, manufacture and distribution of unregistered medicines. It 
should also cease selling the tenders‟ product to the private pharmacies. The latter practice 
undermines the inspection outcomes, because it makes inspectors task too difficult (i.e., can not 
identify the source of medicine whether it is CMSPO or not). 
 
The public sector is rigid, bureaucratic personnel-management practices, low incentives, poor job 
satisfaction and unsupportive work environment compared to the private sector. Such situation 
demoralised pharmacists and encourages them to join the private sector. Many (65%) of surveyed private-
sector pharmacists claimed they were public sector pharmacists migrated to the private sector. Although 
information on migration is sparse, anecdotal evidence persuasively underscores the problem. An internal 
flow of pharmacists plagues all states, since pharmacists move from poorer states to wealthier ones and 
from the public sector to the private. Strategies to meet current and future challenges in pharmacy human 
resources are urgently needed. Approaches that focus on the training of individuals, which do not take into 
account the job satisfaction (i.e. the nature of the work itself) and pharmacists' mobility, can enjoy only 
limited success. Increased production alone cannot compensate for weak motivation, high attrition and 
increasing mobility. To reverse decades of neglect, policy-makers in both (state and federal level) should 
begin now, first by recognising the problem and secondly by fixing it through the immediate 
implementation of potentially effective strategies. Although, we do not advocate the creation of new 
barriers to the movement of pharmacists between private and public sectors, steps should be taken to 
redress the unbalanced situation. Ten immediate steps are recommended: 
 
 Large-scale advocacy is needed to achieve heightened political awareness within states and at federal 
level. One potential outcome of large-scale movement would be the beginnings of introduction of 
pharmacy care concept, which reshapes the pharmacy services around the patients in hospitals and 
community pharmacies. This concept will benefit the health care system users and motivate 
pharmacists to do a good job to their clients and employers. The employers need to foster an 
organisational culture that recognises and values staff contribution. Central to the delivery of effective 
 recognition are employees' immediate bosses, where a participative and considerate management style 
is shown as a major predictive factor of retention. 
 The Federal Ministry of Health (FMOH) needs to learn from the past experience of Khartoum, Red 
Sea, Northern, and Algadarif States and current Gezira State then, identify success stories. Pharmacists 
and their organisations, and Ministries of Health have not remained passive in confronting the crisis in 
pharmacy workforces. The goodwill and commitment of public sector pharmacists to provide quality 
care despite low wages (30% of the average private salary) and medicines supply shortages at times of 
appalling conditions should not be overlooked. 
 Pharmacist job satisfaction: Job satisfaction is how people feel about their jobs. Experiencing job 
dissatisfaction leads to withdrawal cognition and employee turnover. Job dissatisfaction can be caused 
in many ways, including high centralisation, routinisation, low integration, low communication and 
policy knowledge. Pharmacy education has a key role to prepare pharmacy student for practice and 
must anticipate the changing professional role. New strategies need to be developed with the 
participation of pharmacy professionals associations, unions, universities and ministries of health and 
higher education representatives to meet both; the short-term and long-term needs of pharmacists as 
pharmacy care providers. Technology will, no doubt give opportunity to join postgraduate studies 
(e.g., P.G. diploma or M.Sc. courses) from overseas via e-learning or continuing pharmacy 
professional development programmes.  
 Salaries and incentives structure: This includes the process of creating new jobs, addressing low 
wages, as well as developing incentives structure that supports pharmacists over the course of their 
working lives. In order to stem the flow of pharmacists to the private sector and increase their 
performance, the Ministry of Health needs to pay incentives to its pharmacy staff on a semi-private 
basis. Introduction of the employment contract and the application of the incentive budget line 
opposite performance proved to be effective in Khartoum State experience. The obligations of each 
part (employer and employee) should be written in non-ambiguous language and transparent reward 
system should be in place. When transparency of reward system is poor, its credibility will be 
questioned and pharmacists might not respond to the explicit incentive system at all. IDS, 2000 
pointed the lack of training and potential career development is a particularly important contributor to 
voluntary resignations. Uncompetitive pay is often debated as a reason for employee turnover. The 
perception of receiving a fair salary is a determinant of retention. It seems to be important both at the 
recruitment stage and subsequently as a determinant of retention rates is the perception that employees 
are receiving a fair salary. It is important to note this doesn‟t necessarily equate to a large salary, since 
people often compare themselves with peers in the same occupations or with friends and family rather 
than with better paid or higher skilled workers. Also, when promises are broken and expectations are 
perceived (haven‟t been met), employees take actions to withdraw from the organisation, which may 
include actually quitting jobs. 
 Pharmacy staff motivation: In addition to financial incentives, Ministry of Health should continue to 
invest in improving the working conditions to ensure the suitable qualified and skilled pharmacists are 
retained for longer periods. Recruitment of qualified pharmacists (which may include looking outside 
the public services). A clear definition of job assignments (staff at hospitals` level enter into written 
contracts to perform according to MOH guidelines) and regular supervision will assist MOH to 
achieve a good staff performance. MOH should provide transport to pharmacists (senior and 
specialised pharmacists could be offered private vehicles) from their residence to the place of work to 
increase their motivation. Company-paid private medical insurance, and a company car for senior 
staff, child day care facilities, pension and retirement plans are the most desired and lead to employee 
retention. 
 Redistribution of Pharmacy workforces: To address the problems of pharmacy profession in Sudan, an 
increase in access to essential medicines is insufficient. Far more important is the need to strengthen 
the pharmacy workforce in localities, states and federal health institutions to address the challenges 
and to use the resources and interventions for provision of effective pharmaceutical services.  
 Small staff and efficient teamwork: The pharmacy workforces are divided into two levels (1) 
Department of pharmacies at Ministry of Health, and (2) Hospitals. The Department of pharmacy at 
state level should consist of 6 pharmacists at maximum and 25 at federal department of pharmacy 
including drug analysis laboratory. The hospitals` department of pharmacies classified as follows: 
 
(i) Group A includes big hospitals (e.g., Khartoum and Omdurman hospitals). The numbers of 
pharmacists in Group A hospitals are 15 pharmacists in addition to pharmacy assistants and other 
 supportive staff to cover all shifts. One manager, 3 pharmacist work in Drug Information Centre, three for 
internal hospital pharmacy, two in outpatient pharmacy, three in people pharmacy and one in clinical 
pharmacist; 
(ii) Group B includes medium hospitals and capital cities hospitals (e.g., Ibrahim Malik, and Medani 
Hospitals). The Hospital Pharmacy Department (HPD) this group managed by 4 to 6 pharmacists;  
(iii) Group C includes small and rural hospitals. Two pharmacists could run the HPD in these 
hospitals. Paying attention to create more flexible and efficient system for PHRs management in the 
government institutions might help improve the condition of shortages of pharmacists in the public sector. 
The advantages of small staff can be easily managed, trained and financed, and teamwork could be 
developed. This also improves the performance and productivity of the public sector pharmacists thereby 
reduces the number of PHRs needed to provide satisfactory pharmaceutical services in the public sector 
institutions. The best indicators of staff retention are the fostering of friendships at work, and managers in 
healthcares should take time to get knowing people and foster opportunities for friendship and socialising.  
 
 National leadership at the highest level is essential and will only come to heighten the awareness of the 
fundamental importance of pharmacists in health care in general and in the pharmaceutical care in 
particular, and the development of new methods and strategies.  
 Continuing pharmacy professional development: The most important element of National Drug Policy 
(NDP) and 25 years pharmacy strategy has yet to be tackled. MOH should fully recognise its 25 years 
pharmacy strategy goals could be achieved through people's (especially pharmacists) expertise. 
Appropriate training and development is the key to reach those goals and make strategy visions 
become reality. A wide variety of external (e.g., distance or e-learning in the developed world) and 
internal training and development programmes for pharmacists should be introduced. A pharmacist's 
career or pathway should be developed. A policy for active selection of training fields should be 
formulated according to the priorities of health care needs. The career development relies on 
individual training and development to enable employees to move into more challenging roles and can 
provide enhanced rewards for those who are promoted. 
 Pharmacy staff discipline and accountability system: Disciplinary procedures, which provide a range 
of possible responses (from warnings through dismissal, depending on the severity and frequency of 
the offence should be clearly stated in the new work contracts). Pharmacy managers and team leaders 
in different settings (administration or care providing, at both state and federal levels) should be 
trained to invoke disciplinary procedures and to bring criminal charges when necessary. 
 
Improving effectiveness of the public pharmacy is by switching resources towards areas of need, 
reducing inequalities and promoting better health. Unless there are clear incentives for pharmacists, they 
can move away from public sector. 
Findings innovative approaches to stop brain drain of the pharmacists from the public sector and to 
increase their productivity and performance might be more appropriate strategies to solve the problem in 
Sudan. These strategies comprise, for instance, monitory incentives, continuing professional development, 
working condition and job satisfaction of civil service PHRs.  
The study may help the Ministry of Health to better look at the real issues of PHRs in the public sector 
and formulate more relevant and useful policies and plans to retain qualified and skilled pharmacists in the 
public sector on a solid evidence base. Monitoring and evaluation of information provided to MOH. 
The data must be accurate and up to date. The study revealed low salaries, job dissatisfaction in 
relation to the pharmacy practice and bureaucracy, working conditions, lack of recognition for contribution 
at work, and lack of professional development training programmes are the main factors influencing the 
brain drain of the PHRs.  
These factors affect PHRs immigration and retention concurrently rather than in insolation. 
Given the time constraints required to get the new contracting arrangements in place, there is a risk 
that good practice developments in options for change for change field sites may not be used effectively 
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